Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?
The Motley Fool ·
The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast.
Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?
The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast.
1 sources · 1 articles · updated 2026-11-07 18:30 UTC · business